Stamford-based Sema4, working in partnership with researchers from the Icahn School of Medicine at Mount Sinai in New York City, have published a study in Nature Communications using network modeling to identify novel targets for treating patients with early-stage invasive lung adenocarcinoma, the most common lung cancer among American patients.